Dabrafenib
- Generic Name
- Dabrafenib
- Brand Names
- Tafinlar, Finlee
- Drug Type
- Small Molecule
- Chemical Formula
- C23H20F3N5O2S2
- CAS Number
- 1195765-45-7
- Unique Ingredient Identifier
- QGP4HA4G1B
- Background
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation.
...
- Indication
As monotherapy, dabrafenib is indicated to treat unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
In combination with trametinib, dabrafenib is indicated to treat for:
...
- Associated Conditions
- Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Solid Tumours, Unresectable Melanoma, Unresectable Solid Tumor
- Associated Therapies
- -
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2020-12-08
- Target Recruit Count
- 79
- Registration Number
- NCT03352947
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
Dabrafenib and/or Trametinib Rollover Study
- Conditions
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT03340506
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸National Institute Of Health, Bethesda, Maryland, United States
🇺🇸James Cancer Hospital and Solove Research Institute Ohio State, Columbus, Ohio, United States
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT03272464
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03244956
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Efficacy and Safety of Precision Therapy in Refractory Tumor
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Baodong Qin
- Target Recruit Count
- 300
- Registration Number
- NCT03239015
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT03149029
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03091257
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- West Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03088176
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03026517
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 6
- Registration Number
- NCT02974803
- Locations
- 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Odette Cancer Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.